Extended stability study of oxaliplatin infusions for 'dose-banding'

Xiaoqing Liu¹, Prof. Graham Sewell¹

¹School of Health Professions, Plymouth University, UK



Introduction

Dose-banding¹ requires an extended shelf-life (1 - 3 months) of pre-made drug infusions. This study evaluated the chemical and physical stability of oxaliplatin infusions using a sequential temperature cycling design. This design challenges physical stability and support the re-issue of infusions in cases of treatment delays.

Preparation of oxaliplatin infusion bags

- ▶ 7 groups of oxaliplatin infusion bags (Group A, B, C, D, E, F, G) were prepared with 5% glucose.
- Each group comprised of:
- $\mathbf{3} \times \mathbf{0.2} mg/ml$ infusion bag
- ▶3× 0.7mg/ml infusion bag
- All infusion bags were protected from light.

HPLC method for chemical stability test

A bonded-phase cyano column of Water Spherisorb (CNRP) was used to separate oxaliplatin in a HPLC method which was stability-indicating and fully validated for this particular study.




Figure 1: Oxaliplatin calibration plot over the concentration range of $1.0 - 90.0 \mu g/ml(n = 7)$.

Physical stability evaluation

Physical stability of oxaliplatin infusions was evaluated as shown in Figure 2.




Figure 2: Physical stability tests for oxaliplatin infusion samples.

Sequential temperature cycling protocol

The sequential temperature cycling scheme is shown below.

- ► Step 1: Storage at 2 8°C (refrigerated temperature).
- Step 2: Incubation at 25°C (room temperature).
- ► Step 3: Storage at $2 8^{\circ}C$ after step 2.




Figure 3: Graphical summary of the study process for oxaliplatin infusion groups (Group A - G) with the sequential temperature cycling storage conditions.

Samples were analysed at the end of each step to determine chemical and physical stability.

Result and Discussion

- ► Oxaliplatin infusions at both concentrations were chemically (95 105% of initial concentration) and physically (no significant change) stable throughout the entire study.
- The extended shelf-life (84 days at $2 8^{\circ}C$) of oxaliplatin infusions can support the advance batch preparation of standard infusions required for dose-banding.
- The ability to re-refrigerate the infusions for up to 7 days following 24 hours exposure to room temperature will reduce infusion wastage in cases where treatment is delayed for clinical reasons.

Conclusion

This rigorous study extends the known shelf-life of oxaliplatin infusions and facilitates an oxaliplatin dose-banding scheme. Oxaliplatin infusions, stored for 84 days at $\mathbf{2} - \mathbf{8}^{\circ}\mathbf{C}$, remained stable after incubation of 24 hours at $\mathbf{25}^{\circ}\mathbf{C}$ and a further 7 days at $\mathbf{2} - \mathbf{8}^{\circ}\mathbf{C}$, replicating re-use of infusions after treatment delay.

Plumridge, R J & Sewell, G J, Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapy, Am J Health-Syst Pharm, 58, (18), pp 1760-1764, 2001.